Astrotech Cuts R&D Expense 25% to $1.83M, Deploys TRACER 1000 to 35 Sites in 16 Countries
Astrotech’s Q2 FY2026 R&D expense fell 25% year-over-year to $1.832 million as it shifts products to market and has deployed the TRACER 1000 system to 35 locations in 16 countries. The company appointed Scott Bartley interim CFO and David Spada global sales director to drive revenue growth.
1. Q2 Financial Highlights
In the second quarter of fiscal 2026, Astrotech reduced its research and development expense by 25% to $1.832 million as it moves from development toward saleable products in its EN-SCAN Handheld GC and 1st Detect Tracer 1000 lines. This reduction reflects the company’s transition strategy and cost optimization ahead of anticipated product revenues.
2. Global TRACER 1000 Deployments
By December 31, 2025, Astrotech deployed its TRACER 1000 trace detection system in approximately 35 locations across 16 countries spanning the United States, Europe and Asia. The company reports growing interest in its mass spectrometry and gas chromatography solutions for explosives and narcotics screening, driven by evolving safety and law enforcement needs.
3. Leadership Appointments
Astrotech strengthened its executive team with Scott Bartley’s appointment as interim chief financial officer to oversee financial strategy and reporting, and David Spada’s elevation to director of global sales at its 1st Detect subsidiary to accelerate international market expansion and support sustained revenue growth.